pharmaceuticals

pharmaceuticals Articles

After Acadia Pharmaceuticals released its third-quarter earnings report after the markets closed on Monday, shares rose sharply Tuesday morning.
RBC thinks investors can buy these biotech stocks now, because the timing in their view is irrelevant, and they see the stocks de-risked and having mergers and acquisitions potential.
Over the past month, Valeant Pharmaceuticals sank to just above its 52-week low, but it appears that it has now been pushed over the edge with this most recent earnings report.
Horizon Pharma PLC (NASDAQ: HZNP) reported its third-quarter financial results on Monday before the markets opened. The company said that it had $0.70 in earnings per share (EPS) and $208.7 million...
Halfway through the third quarter, it looked like Joe Papa had really turned this company around, as Valeant Pharmaceuticals shares were up nearly double from their lows, but it has been a different...
Concordia International announced its third-quarter financial results before the markets opened on Monday, as well as a key change in leadership.
Ariad Pharmaceuticals said it had a loss in the most recent quarter. However, incredibly positive growth for its flagship drug pulled this company through.
Shares of Ionis Pharmaceuticals and Biogen were on the move Monday morning after the companies announced positive interim results from a late-stage trial.
Acceleron Pharma released its third-quarter earnings report after the markets closed on Thursday, and shares rallied on Friday.
Regeneron Pharmaceuticals reported mixed third-quarter financial results before the markets opened on Friday.
Aurinia Pharmaceuticals shares saw a handy gain on Thursday morning after the company announced plans for a late-stage trial in the treatment of lupus nephritis.
As Pfizer is a major player in the pharmaceutical industry, this earnings report is important in setting a direction that other companies can rally behind.
The relentless populist rhetoric has lowered the prices on some of the top pharmaceutical companies, and long-term growth and income investors have a chance to buy some great stocks on sale.
Ophthotech Corp. (NASDAQ: OPHT) is watching its shares rise in Monday’s trading session after the company reported results from its mid-stage trial of Fovista in combination with Lucentis for the...
Pfizer is scheduled to release its third-quarter financial results before the markets open on Tuesday.